Gold prices edge higher on raised Fed rate cut hopes
Collegium Pharmaceutical , Inc. (NASDAQ:COLL) announced Monday that its Board of Directors has authorized a new share repurchase program, permitting the company to buy back up to $150 million of its common stock through December 31, 2026. According to InvestingPro data, this move aligns with management’s track record of aggressive share buybacks, supported by the company’s robust free cash flow yield of 20%.
According to a statement included in a Securities and Exchange Commission filing, the timing and amount of any repurchases will be determined based on market conditions, the company’s share price, and other factors. Collegium Pharmaceutical plans to use existing cash on hand to fund the program.
Collegium Pharmaceutical is incorporated in Virginia and is headquartered in Stoughton, Massachusetts. The company’s common stock is listed on the NASDAQ Global Select Market under the ticker COLL.
This information is based on a press release statement contained in a recent SEC filing.
In other recent news, Collegium Pharmaceutical reported strong financial results for the first quarter of 2025, with net product revenues reaching $177.8 million, a 23% increase compared to the previous year. This growth was largely driven by the company’s ADHD medication, Jornay PM, which saw a 24% rise in prescriptions. The company has also launched a $25 million accelerated share repurchase program as part of a broader $150 million buyback initiative. This program is expected to be completed by the third quarter of 2025, and is part of Collegium’s strategy to return value to shareholders. Additionally, Collegium’s Board of Directors has authorized a new share repurchase program of up to $150 million, replacing a previous authorization that expired in June 2025. The company has expressed confidence in its growth trajectory, emphasizing its commitment to expanding its commercial portfolio and deploying capital effectively. Analysts from Jefferies LLC are involved in the share repurchase agreement, highlighting the strategic capital allocation by Collegium. The company’s Chief Financial Officer, Colleen Tupper, noted that the financial position allows significant flexibility in executing these strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.